Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder - NCT00755040-37232 (Clinical Trial 242478)


Welcome To Clinical Connection



Our clinical trials database is updated daily
Over 250,000 individuals are currently being connected to clinical trials by ClinicalConnection.com!


Trials Alerts	Trials Search
Health Forum	Health News
RSS	Intro
Clinics & Sponsors	Member Login

View Clinical Trial (Medical Research Study)

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder - NCT00755040-37232 (Clinical Trial 242478)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy242478.aspx

** Please review additional "Nearby Studies" on right ----->

City:

Nashville

State:

Zip Code:

37232

Conditions:

Chronic Myeloproliferative Disorders - Graft Versus Host Disease - Leukemia - Lymphoma - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Diseases

Purpose:

RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder. PURPOSE: This randomized phase I trial is studying how well cyclosporine eye drops work in preventing graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.

Study summary:

OBJECTIVES: Primary - To assess the efficacy of cyclosporine ophthalmic emulsion (Restasis®) in the prevention of ocular graft-versus-host disease in patients who have undergone allogeneic stem cell transplantation for hematologic malignancies or bone marrow failure disorders. Secondary - To correlate the Ocular Surface Disease Index with clinical ophthalmologic examination. OUTLINE: This is a multicenter study. Patients are stratified according to age, type of transplant (related vs unrelated), and intensity of transplant (ablative vs other). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive cyclosporine ophthalmic emulsion (Restasis®) drops in each eye twice daily for up to 1 year after transplant. - Arm II: Patients receive placebo ophthalmic drops in each eye twice daily for up to 1 year after transplant. Patients in both arms may also receive artificial tear drops at least twice daily as clinically necessary.

Criteria:

DISEASE CHARACTERISTICS: - Diagnosis of hematologic malignancy or bone marrow failure disorder - Has undergone allogeneic stem cell transplantation within the past 80-120 days - No diagnosis of ocular graft-versus-host disease (GVHD) - No grade 4 acute GVHD - No relapse of underlying disease PATIENT CHARACTERISTICS: - Life expectancy ≥ 6 months - No documented dry eye prior to undergoing stem cell transplantation - No history of documented ocular infections prior to or during stem cell transplantation - No significant non-GVHD ocular problem that would preclude study participation - No history of non-compliance PRIOR CONCURRENT THERAPY: - See Disease Characteristics

Study is available at:

Vanderbilt-Ingram Cancer Center
Nashville, TN 37232
United States

Primary Contact:
Clinical Trials Office - Vanderbilt-Ingram Cancer Center
Phone: 800-811-8480

If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.

Trials Alerts:

If you would like to be notified of new clinical trials as they become available please register for a free account.

Data Source:		ClinicalTrials.gov
Date Processed:		March 16, 2010
Modifications to this listing:		Only selected fields are shown, please use the link above to view all information about this clinical trial.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.


Featured Nearby Studies:

Within 25 Miles

Within 50 Miles

Within 100 Miles

Diabetic Gastroparesis - Huntsville AL

Diabetic Gastroparesis - Huntsville AL

Metastatic Colorectal Cancer - PEAK Study - Huntsville AL

Metastatic Colorectal Cancer - PEAK Study - Huntsville AL


Clinical Trials Search

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted nationwide.
ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.